Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD8586 in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05824585Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- May 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of birelentinib in non-Hodgkin lymphoma (NHL), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Incidence of adverse events and Objective Response Rate up to 2 years. Started May 2023; status: completed.
02
Drugs
birelentinib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05824585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824585.